Taiwan Advance Bio-Pharmaceutical (ROCO:4186) EPS (Basic): NT$0.31 (TTM As of Dec. 2025)


ROCO:4186 Taiwan Advance Bio-Pharmaceutical Inc ROCO:4186
52 GF Score
Price NT$10.15
GF Value NT$17.86
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Taiwan Advance Bio-Pharmaceutical EPS (Basic)?

Taiwan Advance Bio-Pharmaceutical ROCO:4186 52 EPS (Basic) is NT$0.31 as of Dec. 2025. GuruFocus rates ROCO:4186 with a GF Score™ of 52/100 and a GF Value™ of NT$17.86 (Possible Value Trap). The stock has 4 warning signs investors should review.

Taiwan Advance Bio-Pharmaceutical's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was NT$0.35. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.31.

Taiwan Advance Bio-Pharmaceutical's EPS (Diluted) for the six months ended in Dec. 2025 was NT$0.35. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.31.

Taiwan Advance Bio-Pharmaceutical's EPS without NRI for the six months ended in Dec. 2025 was NT$0.39. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.40.

During the past 12 months, Taiwan Advance Bio-Pharmaceutical's average EPS without NRIGrowth Rate was 36.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 100.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Taiwan Advance Bio-Pharmaceutical's highest 3-Year average EPS without NRI Growth Rate was 100.20% per year. The lowest was -73.70% per year. And the median was 2.70% per year.

Taiwan Advance Bio-Pharmaceutical  (ROCO:4186) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Taiwan Advance Bio-Pharmaceutical EPS (Basic) Related Terms

Taiwan Advance Bio-Pharmaceutical EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Taiwan Advance Bio-Pharmaceutical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical EPS (Basic) Chart

Taiwan Advance Bio-Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.32 0.04 -0.12 0.25 0.31

Taiwan Advance Bio-Pharmaceutical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 -0.05 0.30 -0.04 0.35
ROCO:4186
52GF Score
Taiwan Advance Bio-Pharmaceutical Inc ROCO:4186
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiwan Advance Bio-Pharmaceutical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Taiwan Advance Bio-Pharmaceutical's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(28.047-0)/90.000
=0.31

Taiwan Advance Bio-Pharmaceutical's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(31.938-0)/90.000
=0.35

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$0.31 mean?
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a EPS (Basic) of NT$0.31 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors.
Is Taiwan Advance Bio-Pharmaceutical's EPS (Basic) too high?
Taiwan Advance Bio-Pharmaceutical's current EPS (Basic) is NT$0.31. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's EPS (Basic) compare to VRTX and REGN?
Taiwan Advance Bio-Pharmaceutical's EPS (Basic) of NT$0.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. Taiwan Advance Bio-Pharmaceutical's current EPS (Basic) is NT$0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.86, compared to a current price of NT$10.15 — trading 43.2% below its estimated fair value. The current EPS (Basic) is NT$0.31. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current EPS (Basic) is NT$0.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued. The current stock price of NT$10.15 is trading 43.2% below its estimated GF Value™ of NT$17.86. GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:4186:

  • EPS (Basic): NT$0.31
  • GF Value™: NT$17.86 vs. price of NT$10.15 (43.2% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiwan Advance Bio-Pharmaceutical Business Description

Address No. 363, Section 2, Fuxing South Road, 5th Floor, Daan District, New Taipei City, TWN, 22180
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
52GF Score

Get the complete analysis for ROCO:4186

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.15
Price
NT$17.86
GF Value